Crinetics Pharmaceuticals【CRNX】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

57.07

買値

57.06

売値

57.17

出来高

285,070

55.305 日の範囲 57.76

29.72 52 週間の範囲 62.53

時価総額

5.293B

前日終値

56.07

始値

56.00

時刻

199

57.07

最終取引時間

03:03:36

財務取引量

US$ 16,132,478

VWAP

56.5913

平均取引量 (3 か月)

725,124

発行済株式数

92,737,627

配当利回り

PER

-24.65

1 株当たり利益 (EPS)

-2.31

歳入

4.01M

純利益

-214.53M

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.crinetics.com

本社

Wilmington, Delaware, USA

設立

Crinetics Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker CRNX. The last closing price for Crinetics Pharmaceuticals was US$56.07. Over the last year, Crinetics Pharmaceuticals shares have traded in a share price range of US$ 29.72 to US$ 62.53.

Crinetics Pharmaceuticals currently has 92,737,627 shares in issue. The market capitalisation of Crinetics Pharmaceuticals is US$5.20 billion. Crinetics Pharmaceuticals has a price to earnings ratio (PE ratio) of -24.65.

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization...

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.21	-2.0761839396	58.28	62.53	52.845	726636	55.92660319	CS
4	-1.43	-2.44444444444	58.5	62.53	52.845	621813	57.62783337	CS
12	2.5	4.58127176104	54.57	62.53	49.125	725124	54.63927012	CS
26	6.5	12.853470437	50.57	62.53	41.01	752102	51.53178103	CS
52	26.92	89.2868988391	30.15	62.53	29.72	786763	45.81997027	CS
156	29.54	107.301126044	27.53	62.53	15.23	600935	32.80172799	CS
260	37.89	197.549530761	19.18	62.53	10.63	421954	30.60972565	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
WORXSCWorx Corporation	US$ 2.0101 (105.11%)	118.82M
CRNCCerence Inc	US$ 5.4593 (93.59%)	46.34M
SPAISafe Pro Group Inc	US$ 4.56 (42.50%)	40.19M
QUBTQuantum Computing Inc	US$ 5.0346 (36.81%)	108.34M
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 44.32 (29.93%)	2.8M
SKKSKK Holdings Limited	US$ 1.8921 (-58.51%)	12.89M
WCTWellchange Holdings Company Limited	US$ 1.401 (-57.80%)	1.15M
GLXGGalaxy Payroll Group Ltd	US$ 1.95 (-50.13%)	1.83M
PYXSPyxis Oncology Inc	US$ 2.165 (-43.32%)	11.27M
TMTCTMT Acquisition Corporation	US$ 3.90 (-39.44%)	37.03k
CDTConduit Pharmaceuticals Inc	US$ 0.1164 (26.11%)	533.55M
NVDANVIDIA Corporation	US$ 143.7709 (-1.45%)	249.11M
AKTSAkoustis Technologies Inc	US$ 0.1047 (20.21%)	192.18M
ELABElevai Labs Inc	US$ 0.0203 (-5.14%)	187.68M
WORXSCWorx Corporation	US$ 2.01 (105.10%)	117.93M